Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2021

View Archived Issues

Debiopharm identifies new enoyl-(acyl-carrier protein) reductase FabI inhibitors

Beijing Tide Pharmaceutical patents PROTACs targeting mutant EGFR

New furaneol glycoside compounds divulged by Fudan University

Janssen Pharmaceutical discovers compounds for hepatitis B

Condensate drugs block RSV replication in vivo

ALG2-CDG model in zebrafish displays human phenotypes and hypo-N-glycosylation

EscharEx debridement agent demonstrates efficiency, safety in chronic wound study

Hummingbird and MD Anderson collaborate to advance VISTA antagonist antibody, HMBD-002

First patient treated in phase I study of INKmune in high-risk MDS

Dosing begins in phase I study of CB-010 in B-cell NHL

Identification of antivirulence compound ANT-3273 for P. aeruginosa infection

Aptorum reports further interim phase I data on ALS-4

Prokineticin-2 as therapeutic target for prevention of neuronal death

Qixleef phase II protocol modifications approved

Immunic presents new preclinical and clinical data for IMU-935

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

Vaccibody and Adaptive Biotechnologies sign license agreement on SARS-CoV-2 T-cell epitopes

Uproleselan studied with venetoclax and azacitidine for older or unfit patients with AML

Safety and immunogenicity of BNT-162b1 confirmed in phase I study in Chinese adults

FDA clears Tevogen Bio's IND application for TVGN-489 for COVID-19

Cellectar collaborates with LegoChemBio on first-in-class phospholipid drug conjugates

High annexin-2 levels worsen lung injury in patients with COVID-19

Akeso completes phase I trial of AK-117 and gains clearance for phase Ib/II trial in AML

Carna reports phase I SAD data on BTK inhibitor AS-0871

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026